Table 1. Clinical Characteristics of 23... | American Society of Hematology

Table 1.

Clinical Characteristics of 23 Patients With T-Cell ALL at Diagnosis

Patient No.	Date of Diagnosis	Gender	Age	WBC Count (per μL)	Immunophenotype	Treatment Protocol^*
			(yr)
CT1	20/9/91	F	7	36,000	CD7⁺ TdT⁺ CD2⁻ CD5⁺ CD3⁻	9103
CT2	18/7/91	F	14	17,200	CD7⁺ TdT⁻ CD2⁺ CD5⁺ CD3⁺	9103
CT3	13/1/86	F	8	33,000	T-rosette⁺	LSA2L2
CT4	26/1/94	F	14	1,720	CD7⁺ TdT⁺ CD2⁻ CD5⁻ CD3⁺ CD4⁺ CD8⁺	9103
CT5	15/9/93	M	9	34,800	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻	9102
CT6	17/2/87	M	10	1,000	CD7⁺ TdT⁻ CD2⁻ CD5⁺ CD3⁺ CD4⁺ CD8⁺	8703
CT7	11/11/93	M	10	3,000	CD7⁺ TdT⁻ CD2⁺ CD5⁺ CD3⁺ CD4⁺ CD8⁺	9102
CT8	23/7/87	M	5	175,200	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻	8703
CT9	12/9/94	M	12	81,200	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁺	9102
CT10	18/10/84	M	4	40,000	T-rosette⁺	LSA2L2
CT11	29/4/89	F	3	158,000	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻ CD4⁺	8703
CT12	8/5/94	M	15	45,700	CD7⁺ TdT⁺ CD2⁻ CD5⁺ CD3⁺	9103
CT13	21/8/85	M	8	78,500	T-rosette⁺ (CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻ at relapse)	LSA2L2
CT14	21/5/93	F	7	209,000	CD7⁺ TdT⁻ CD2⁺ CD5⁺ CD3⁺	9103
CT15	17/10/90	F	2	90,000	CD7⁺ TdT⁺ CD5⁺ CD3⁻	9103
CT16	26/4/93	M	9	57,600	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻	9102
CT17	1/5/89	M	10	52,800	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD4⁺ CD8⁻	8703
CT18	31/10/91	F	4	173,600	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻	9103
CT19	15/9/93	F	1	137,000	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻	9102
CT20	19/3/91	M	8	178,000	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁺	9103
CT21	2/9/93	M	5	4,500	CD7⁺ TdT⁺ CD2⁻ CD5⁺ CD3⁺ CD4⁺ CD8⁺	9102
CT22	18/7/94	M	2	150,000	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁺	9102
CT23	17/9/90	M	4	34,200	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻	8703

Patient No.	Date of Diagnosis	Gender	Age	WBC Count (per μL)	Immunophenotype	Treatment Protocol^*
			(yr)
CT1	20/9/91	F	7	36,000	CD7⁺ TdT⁺ CD2⁻ CD5⁺ CD3⁻	9103
CT2	18/7/91	F	14	17,200	CD7⁺ TdT⁻ CD2⁺ CD5⁺ CD3⁺	9103
CT3	13/1/86	F	8	33,000	T-rosette⁺	LSA2L2
CT4	26/1/94	F	14	1,720	CD7⁺ TdT⁺ CD2⁻ CD5⁻ CD3⁺ CD4⁺ CD8⁺	9103
CT5	15/9/93	M	9	34,800	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻	9102
CT6	17/2/87	M	10	1,000	CD7⁺ TdT⁻ CD2⁻ CD5⁺ CD3⁺ CD4⁺ CD8⁺	8703
CT7	11/11/93	M	10	3,000	CD7⁺ TdT⁻ CD2⁺ CD5⁺ CD3⁺ CD4⁺ CD8⁺	9102
CT8	23/7/87	M	5	175,200	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻	8703
CT9	12/9/94	M	12	81,200	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁺	9102
CT10	18/10/84	M	4	40,000	T-rosette⁺	LSA2L2
CT11	29/4/89	F	3	158,000	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻ CD4⁺	8703
CT12	8/5/94	M	15	45,700	CD7⁺ TdT⁺ CD2⁻ CD5⁺ CD3⁺	9103
CT13	21/8/85	M	8	78,500	T-rosette⁺ (CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻ at relapse)	LSA2L2
CT14	21/5/93	F	7	209,000	CD7⁺ TdT⁻ CD2⁺ CD5⁺ CD3⁺	9103
CT15	17/10/90	F	2	90,000	CD7⁺ TdT⁺ CD5⁺ CD3⁻	9103
CT16	26/4/93	M	9	57,600	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻	9102
CT17	1/5/89	M	10	52,800	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD4⁺ CD8⁻	8703
CT18	31/10/91	F	4	173,600	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻	9103
CT19	15/9/93	F	1	137,000	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻	9102
CT20	19/3/91	M	8	178,000	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁺	9103
CT21	2/9/93	M	5	4,500	CD7⁺ TdT⁺ CD2⁻ CD5⁺ CD3⁺ CD4⁺ CD8⁺	9102
CT22	18/7/94	M	2	150,000	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁺	9102
CT23	17/9/90	M	4	34,200	CD7⁺ TdT⁺ CD2⁺ CD5⁺ CD3⁻	8703

See Fig 1.